Tag Archives: Xtandi

Drug Regulation Patent

Standing Against XTANDI: An E-mail Campaign to Ensure Accessibility to Cancer Wonder-Drug

by
Leave a Comment

In their latest efforts to stop the University of California, Los Angeles (UCLA) from pursuing a patent for Xtandi, the Universities Allied for Essential Medicines (UAEM) is sending an e-mail petition to Janet Napolitano, the President of University of California. This attempt comes after UAEM made a representation before the Regents of the University of California for a third time, demanding that Xtandi be made more accessible in India. Xtandi has an eventful if not long history of controversies in…


Read More »
Drug Regulation Patent

XTANDI Updates: Cancer Union and 56 others request UCLA to back down from Delhi HC review of IPO’s patent rejection order; Delhi HC refuses to hear the matter on priority

by
2 Comments

In a positive development, the Union for Affordable Cancer Treatment (UACT), along with 56 other organizations, has requested the University of California (UCLA) to withdraw from its proceedings before the Delhi High Court against the IPO’s rejection of its patent[1] in XTANDI. In its letter dated 24th May 2017, UACT reminds UCLA that its research for the blockbuster drug for prostate cancer was supported by US taxpayer dollars through the National Cancer Institute at the National Institutes of Health and…


Read More »
Patent

Delhi HC Seeks Explanation for Denial of Xtandi Patent

by
Leave a Comment

The Delhi High Court passed a pertinent order on 2nd March, 2017 in the case of The Regents of the University of California v. Union of India (read the order here). While the order does not go into details, and merely directs the counter-affidavit to be filed within four weeks, media reports indicate that the Court has asked the Centre to explain on what basis the Indian Patent Office rejected the University’s patent application for Xtandi, their prostate cancer drug….


Read More »
Patent

Patent Office Rejects Patent Application for Prostate Cancer Drug Xtandi

by
4 Comments

Regular readers of this Blog will recall that, in his guest post on the topic of exorbitant drug pricing, Zakir Thomas had alluded to Xtandi (enzalutamide), a wonder drug developed at the University of California, Los Angeles (UCLA) for fighting prostate cancer which is commercially sold in India by Astellas Pharma. Noting how Astellas’ justification for the unaffordable cost of the drug viz. that it is commensurate with the cost of innovation and patient benefit is emblematic of the apathy…


Read More »